WASHINGTON, Oct. 22, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2025 on Wednesday, October 29, 2025, after the ...

WASHINGTON, Oct. 22, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2025 on Wednesday, October 29, 2025, after the ...

17 Vanda Place, Maddington is a 3 bedroom house. What are the key property features of 17 Vanda Place, Maddington? To enquire about specific property features for 17 Vanda Place, Maddington, contact ...

BELMONT PARK, N.Y., Oct. 8, 2025 /CNW/ -- The New York Islanders today announced a multi-year agreement with Vanda Pharmaceuticals, a global biopharmaceutical company, naming them the team's exclusive ...

Vanda Pharmaceuticals, a company that develops medicines for conditions with limited to no treatment options, has signed a multi-year partnership with the New York Islanders to become their jersey ...

The New York Islanders today announced a multi-year agreement with Vanda Pharmaceuticals, a global biopharmaceutical company, naming them the team’s exclusive jersey patch partner. This landmark ...

Add articles to your saved list and come back to them any time. Sixty years ago this week, Harry Vanda was in a world gone mad. As the Easybeats promoted their 1965 debut album Easy and its ...

Vanda Pharmaceuticals and the FDA have agreed to lay down their swords, squashing years of legal disputes with an agreement that will see regulatory action on much of Vanda’s grievances. The ...

Investing.com - H.C. Wainwright has maintained its Buy rating and $20.00 price target on Vanda Pharmaceuticals (NASDAQ:VNDA), representing nearly 300% upside from the current price of $5.10, following ...

Vanda and FDA's agreement includes expedited re-reviews of Tradipitant and Hetlioz applications, with target action dates in late 2025 and early 2026. The collaborative framework involves pausing ...

Vanda Pharmaceuticals has agreed to a plan in which the Food and Drug Administration will conduct more reviews of two of its drugs to resolve disputes between the company and the agency. Under the ...

Vanda Pharmaceuticals has won a key U.S. Food and Drug Administration designation for its proposed VGT-1849B treatment of the rare blood disease polycythemia vera. Vanda on Thursday said the FDA ...